US Oncology Research
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, US Oncology Research sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
US Oncology Research: 27 sponsored US clinical trials, 1 recruiting.
US Oncology Research sponsors 27 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 19 completed. 3 of these trials are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Carcinoma, Non-Small Cell Lung, with 2 trials.
Top-decile sponsor footprint
US Oncology Research ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
27 total, page 1 of 1
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04782687
MYLUNG Consortium Study Protocol 2
NCT05644808
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
NCT03379428
PhII ICb With/Without Erbitux in MBC Pts
NCT00248287
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
NCT02425683
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
NCT02187991
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
NCT02229149
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
NCT02229136
STAR Cape+BKM120 MBC With Brain Met
NCT02000882
Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)
NCT01909362
Synera Venipuncture Pain
NCT01744197
Triple Negative Breast Cancer Biomarker Study
NCT01111175
Ixabepilone + Carboplatin Metastatic Breast Cancer
NCT01075100
Sunitinib Non Small Cell Lung Cancer Patients Over 70
NCT00864721
Gemzar, Cisp, Sunitinib Urothelial Ca
NCT00821327
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
NCT00661492
Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
NCT00517829
Adj TC + Herceptin Early Stage Breast Cancer
NCT00493649
TAC Versus TC for Adjuvant Breast Cancer
NCT00493870
Phase II Sunitinib Prog Met AIPC
NCT00599313
Pre-op Rectal ChemoRad +/- Cetuximab
NCT00527111
Vidaza to Restore Hormone Thx Prostate
NCT00384839
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
NCT00303108
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
NCT00250861
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
NCT00252564
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
NCT00254163
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 19 |
| Phase 3 | 3 |
What is open in the US Oncology Research pipeline
1 recruiting of 27 indexed (4% open); 19 completed (70%).
Phase mix: 3 late (III/IV) vs 20 early (I/II) (early-phase heavy).
Top condition: Carcinoma, Non-Small Cell Lung (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
US Oncology Research: open-pipeline peers nationwide
Peers matched on 27 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
US Oncology Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 trials (± recruiting share)
- Akron Children's Hospital · 27 trials · 7% recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 27 trials · 0% recruiting
- AVEO Pharmaceuticals · 27 trials · 7% recruiting
- Dompé Farmaceutici S.p.A · 27 trials · 15% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Stryker Orthopaedics · 4% recruiting · 27 trials
- GlaxoSmithKline · 4% recruiting · 1,345 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this US Oncology Research page
27 registered trials is a research-attention snapshot, not an endorsement of US Oncology Research or any single study.
- 1 of US Oncology Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Carcinoma, Non-Small Cell Lung is the condition US Oncology Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Carcinoma, Non-Small Cell Lung trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. US Oncology Research pipeline card: 27 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.